Halozyme jumps on PEGPH20 update in pancreatic cancer
This article was originally published in Scrip
Executive Summary
San Diego-based Halozyme Therapeutics jumped 24.5% to $12.52 per share on 7 January based on Phase II data revealed during an analyst and investor update that showed efficacy for PEGPH20 in patients with metastatic pancreatic cancer whose tumors have high levels of hyaluronan (HA).